Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Advanced Cytoskeletal and Stem Cell Research

Executive Summary: Y-27632 dihydrochloride is a small-molecule inhibitor that selectively targets ROCK1 (IC50 ≈ 140 nM) and ROCK2 (Ki ≈ 300 nM) with over 200-fold specificity relative to other kinases, including PKC and MLCK (APExBIO). This compound disrupts Rho-mediated cellular stress fiber formation and modulates cell cycle progression, making it essential for studies of cytoskeletal dynamics and stem cell viability (Zhu et al., 2023). Y-27632 enhances survival and integration of human pluripotent stem cell (hPSC)-derived interneurons in transplantation models, showing no evidence of uncontrolled growth or over-inhibition (Zhu et al., 2023). It is soluble at ≥111.2 mg/mL in DMSO, with recommended storage at 4°C or below in desiccated form (APExBIO). Y-27632 is a benchmark tool for dissecting the Rho/ROCK pathway in cancer, stem cell, and neurobiology research (Related Article).

Biological Rationale

ROCK1 and ROCK2 are serine/threonine kinases activated by RhoA-GTP. They play central roles in actin cytoskeleton remodeling, cell motility, and cell cycle progression (Zhu et al., 2023). Dysregulation of the Rho/ROCK pathway is implicated in cancer metastasis, neurodegeneration, and stem cell differentiation. Inhibiting ROCK kinases with Y-27632 dihydrochloride allows researchers to probe these mechanisms with high specificity. The compound is cell-permeable and suitable for both in vitro and in vivo studies (Strategic Modulation of the Rho/ROCK Pathway). This article extends the mechanistic and translational insights offered in prior reviews by providing up-to-date benchmarks and workflow guidance.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a competitive ATP-binding inhibitor of ROCK1 and ROCK2. It binds to the catalytic domain of these kinases, preventing phosphorylation of downstream substrates such as myosin light chain (MLC) and LIM kinase. This results in inhibition of actin-myosin contractility and disruption of stress fiber and focal adhesion assembly (APExBIO). The inhibition is highly selective, with over 200-fold lower affinity for kinases like PKC, PKA, MLCK, and PAK. Y-27632 modulates the G1/S phase transition, impacts cytokinesis, and prevents apoptosis in sensitive cell types. Its cell-permeability enables rapid uptake and functional effects at nanomolar concentrations.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an in vitro IC50 of ~140 nM and ROCK2 with a Ki of 300 nM, while showing >200-fold selectivity over PKC, PKA, MLCK, and PAK (APExBIO).
• In human pluripotent stem cell cultures, Y-27632 (10 μM, 24–72 h) significantly increases viability and survival during dissociation and transplantation (Zhu et al., 2023).
• Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner in vitro (1–10 μM), as measured by BrdU incorporation (APExBIO).
• In vivo administration of Y-27632 in mouse tumor models decreases invasive tumor structures and reduces metastasis rates, indicating anti-tumoral efficacy (Zhu et al., 2023).
• Long-term exposure (weeks) of hPSC-derived interneurons to Y-27632 does not lead to over-inhibition or uncontrolled growth post-transplantation (Zhu et al., 2023).

This article updates and clarifies findings presented in Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Stem Cell Expansion by highlighting recent translational outcomes and precise selectivity data.

Applications, Limits & Misconceptions

• Enhancement of stem cell viability, especially for hPSCs and iPSCs during dissociation, cryopreservation, and transplantation. Y-27632 is routinely used at 10 μM for 24–72 hours post-dissociation (Zhu et al., 2023).
• Dissection of Rho/ROCK-dependent cytoskeletal dynamics in migration, adhesion, and contractility assays (Advanced Cytoskeletal Modulation). This article provides updated storage and selectivity details.
• Suppression of tumor invasion and metastasis in preclinical cancer models by disrupting ROCK-mediated actin remodeling (Strategic Inhibition in Cancer Research). We clarify the compound’s specific use in metastasis assays versus general cytotoxic agents.
• Reduction of fibrotic responses and smooth muscle proliferation in organoid and tissue engineering protocols (APExBIO).

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: Y-27632 is highly selective for ROCK1/2 and is ineffective against unrelated kinases at standard concentrations.
• No effect on neuronal excitability in the absence of Rho/ROCK pathway activity: It does not suppress neural firing unless the pathway is active in the context studied.
• Not a substitute for anti-apoptotic agents in all cell types: Y-27632 enhances survival in stem cells but is not universally anti-apoptotic.
• Prolonged exposure not always beneficial: Extended treatment (>72 h) may not improve or could even impair differentiation in some stem cell protocols.
• Ineffective in models where ROCK is not a driver of pathology: The compound does not reverse phenotypes where the Rho/ROCK axis is not involved.

Workflow Integration & Parameters

Y-27632 dihydrochloride (A3008 kit, APExBIO) is supplied as a solid. For stock solutions, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Brief warming (37°C) or ultrasonic bath may accelerate dissolution. Store solid desiccated at 4°C or below; aliquots in solution are stable below -20°C for months but avoid repeated freeze-thaw cycles. Typical working concentrations in cell culture range from 1–20 μM, with 10 μM being standard for hPSC dissociation. For in vivo studies, adjust dose according to animal weight and route, referencing validated protocols (Zhu et al., 2023). For assays involving cytoskeletal analysis, add Y-27632 post-plating for optimal stress fiber disruption.

For additional protocols and troubleshooting guidance, see Strategic Modulation of the Rho/ROCK Pathway, which this article extends by providing new benchmarks and product-specific storage parameters.

Conclusion & Outlook

Y-27632 dihydrochloride is an industry-standard, cell-permeable, selective inhibitor of ROCK1 and ROCK2. Its robust performance and high selectivity make it a critical tool for dissecting Rho-mediated cytoskeletal and cell cycle processes. Recent evidence underscores its safety in long-term stem cell transplantation models, with no evidence of tumorigenicity or over-inhibition (Zhu et al., 2023). As the Rho/ROCK pathway is increasingly implicated in cancer, fibrosis, and tissue engineering, Y-27632 is poised to remain essential in both basic and translational research. For detailed product information and ordering, visit the Y-27632 dihydrochloride product page at APExBIO.